Waist Circumference Measurements in Schizophrenic Patients

Schizophrenia Clinical Trial

Official title:

Variability of Waist Circumference Measurements at 3 Sites and Its Relationship With Cardiovascular Risk Factors in Patients With Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01243034
• Other study ID #: 100717
• Status: Completed
• Start date: August 1, 2010
• Est. completion date: July 31, 2011

Study information

• Verified date: January 2019
• Source: Changhua Christian Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The prevalence of metabolic syndrome(MS) among pt's with schizophrenia has been reported to be high, ranging from 24 to 43% in males and 27 to 52% in females. Schizophrenic patients with MS have an increased incidence of DM, coronary heart disease and increased mortality from cardiovascular diseases. Central adiposity is highly correlated with the presence of hypertension, coronary heart disease, type 2 diabetes, and increased mortality risk. Waist circumference(WC) is a better indicator of abdominal obesity and a better predictor of CVD than either BMI or waist-to-hip ratio. However, currently there is no standard location for the measurement of WC.

Objectives: 1. To compare the magnitude of WC measured at 3 sites ( immediately above the iliac crest, midpoint between the lowest rib and the iliac crest , umbilical level) in males and females.

2. To examine the correlation of WC with Triglyceride, cholesterol, HDL, LDL and glucose.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: July 31, 2011
• Est. primary completion date: July 31, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• • Patients with schizophrenia or schizoaffective disorder (DSM-IV 295) age 18 till 65 years old.

• Body weight change less than 1 kg in previous one month before index date.

Exclusion Criteria:

• • Patients with a previous hyperlipidemia diagnosis or antilipemic prescription during the preceding 30 days.

• Patients received any anti-hypertensives or oral hypoglycemic agents.

• Pregnant or breast-feeding women.

Related Conditions & MeSH terms

• Cardiovascular Risk Factor
• Schizophrenia
• Waist Circumference Measurements

Locations

Country	Name	City	State
Taiwan	Changhua Christian Hospital	Changhua

Sponsors (1)

Lead Sponsor	Collaborator
Changhua Christian Hospital

Country where clinical trial is conducted

Taiwan,